variou
type
vaccin
preclin
clinic
develop
address
recent
appear
middl
east
respiratori
syndrom
mer
emerg
infecti
diseas
alreadi
caus
death
remain
threat
world
health
caus
agent
respiratori
diseas
member
betacoronaviru
genu
phylogenet
close
relat
sar
coronaviru
caus
intern
health
emerg
lesson
learn
outbreak
sever
acut
respiratori
syndrom
undeni
technolog
advanc
vaccin
develop
mer
initi
fastpac
produc
sever
dna
protein
vaccin
candid
promis
result
earli
preclin
test
least
one
vaccin
candid
even
enter
firstinhuman
clinic
trial
number
mer
case
declin
though
infecti
diseas
attract
increas
attent
question
remain
whether
similar
situat
sar
pandem
vaccin
develop
halt
remain
prioriti
right
origin
guangdong
provinc
china
sever
acut
respiratori
syndrom
sar
becam
first
pandem
outbreak
twenti
first
centuri
diseas
caus
infect
respons
almost
death
remark
sar
quickli
becam
diseas
global
import
impact
air
travel
commerc
tourism
outbreak
eventu
contain
use
impress
joint
global
public
health
effort
year
later
anoth
human
coronaviru
cov
emerg
caus
agent
middl
east
respiratori
syndrom
mer
may
alreadi
laboratori
confirm
case
mer
countri
worldwid
relat
death
record
ongo
outbreak
buraydah
saudi
arabia
recurr
episod
like
impress
upon
scientif
commun
need
advanc
develop
licensur
manufactur
stockpil
deploy
vaccin
combat
emerg
infecti
coronaviru
infect
review
progress
area
vaccin
develop
merscov
apprais
assess
lesson
learn
respons
earlier
sarscov
pandem
coronaviru
famili
receiv
global
attent
novemb
first
case
sarscov
infect
report
guangdong
provinc
china
within
month
case
five
death
respiratori
failur
record
subsequ
led
notif
world
health
organ
issuanc
global
health
alert
well
travel
advisori
retrospect
probabl
initi
delay
identif
etiolog
agent
unknown
origin
consequ
allow
worldwid
spread
diseas
scientif
commun
though
subsequ
quick
respond
begin
race
toward
vaccin
develop
full
character
genom
sequenc
sarscov
publish
within
month
start
coordin
effort
determin
epidemiolog
pathogenesi
transmiss
diseas
vaccin
studi
quickli
identifi
viru
spike
protein
possibl
recombin
antigen
compon
futur
vaccin
ctermin
portion
sarscov
nucleocapsid
protein
identifi
like
candid
improv
diagnost
tool
candid
dna
vaccin
show
efficaci
neutral
protect
immun
mice
identifi
within
year
outbreak
vaccin
develop
fuel
daunt
possibl
reemerg
diseas
addit
isol
case
suspect
sar
infect
scare
report
china
point
ten
human
vaccin
trial
plan
use
inactiv
viru
recombin
protein
adenoviru
platform
plasmid
dna
trial
plan
take
place
variou
countri
includ
china
canada
franc
austria
usa
itali
major
hurdl
howev
lack
appropri
anim
challeng
model
could
reproduc
infect
similar
observ
human
identif
viru
reservoir
mechan
transmiss
sar
outbreak
end
juli
month
issuanc
global
alert
outcom
vaccin
develop
race
summar
phase
clinic
trial
report
publish
sever
year
later
two
vaccin
candid
develop
analyz
sinovac
nihniaid
respect
earliest
liveattenu
vaccin
clinic
trial
took
place
fast
track
design
approv
regulatori
author
china
conduct
result
indic
serum
convers
observ
volunt
receiv
low
dosag
vaccin
studi
plasmid
dna
vaccin
candid
develop
niaid
vaccin
research
centr
well
toler
produc
desir
immun
respons
includ
neutral
antibodi
none
candid
though
proceed
phase
ii
recent
recombin
subunitbas
sarscov
vaccin
produc
sabin
vaccin
institut
product
develop
partnership
base
viru
receptorbind
domain
goal
improv
safeti
vaccin
cost
effici
vaccin
develop
process
vaccin
produc
cgmp
condit
clinic
trial
immedi
schedul
middl
east
respiratori
syndrom
mer
first
case
report
june
saudi
arabia
isol
initi
name
trace
back
cluster
pneumonia
case
zarqa
hospit
jordan
marchapril
septemb
report
uk
novel
coronaviru
publish
involv
patient
travel
histori
qatar
shortli
thereaft
isol
found
similar
name
middl
east
respiratori
syndrom
coronaviru
merscov
betacoronaviru
phylogenet
close
relat
sarscov
octob
laboratori
confirm
case
probabl
case
affect
nine
countri
despit
increas
global
vigil
part
certainli
due
prior
experi
sarscov
case
merscov
still
report
outsid
middl
east
year
first
emerg
largest
report
south
korea
june
trace
back
singl
travel
visit
four
variou
middl
eastern
countri
within
month
outbreak
involv
confirm
patient
place
thousand
individu
close
observ
overal
specul
lower
number
case
mer
comparison
sar
may
due
better
coordin
notif
earli
travel
advisori
implement
improv
hospit
contain
measur
issuanc
global
alert
better
complianc
intern
health
provis
origin
draft
although
possibl
mer
could
potenti
follow
pandem
path
sar
base
similar
phylogenet
differ
biolog
viru
adapt
human
be
distinct
merscov
found
alreadi
circul
human
popul
without
mutat
pandem
form
sarscov
adapt
human
be
within
sever
month
show
complex
viru
biolog
affin
merscov
spike
protein
human
receptor
lower
sarscov
rbd
toward
human
receptor
thu
pandem
potenti
merscov
consid
lower
sar
like
reach
epidem
potenti
nevertheless
remain
valid
concern
especi
sinc
fatal
rate
much
higher
sar
tabl
summar
variou
approach
develop
merscov
vaccin
sarscov
inactiv
mean
formaldehyd
uv
light
betapropiolacton
abl
protect
mice
infect
challeng
studi
analog
mer
recombin
propagationdefect
live
viru
lack
structur
envelop
protein
gene
propos
vaccin
candid
prevent
merscov
infect
merscov
genom
approxim
kb
size
encod
sever
uniqu
accessori
protein
four
major
structur
protein
receptorbind
spike
protein
nucleocapsid
n
protein
envelop
e
protein
membran
protein
initi
expect
host
cell
entri
point
merscov
would
similar
angiotensinconvert
enzym
receptor
use
sarscov
confirm
instead
dipeptidyl
receptor
identifi
critic
receptor
entri
merscov
host
cell
share
structur
similar
divers
cellular
tropism
express
surfac
sever
type
cell
sarscov
specif
target
ciliat
epitheli
cell
lung
play
divers
role
includ
regul
peptid
hormon
metabol
cell
activ
neurotransmitt
function
glucos
homeostasi
notabl
merscov
spike
protein
exhibit
high
affin
receptor
wide
rang
host
includ
human
camel
hors
amino
acid
residu
receptorbind
domain
rbd
fragment
subunit
sarscov
spike
protein
abl
induc
neutral
antibodi
protect
sarscov
infect
anim
model
use
homolog
model
correspond
merscov
rbd
locat
residu
protein
sever
variant
rbd
sinc
investig
vaccin
candid
fragment
fuse
human
igg
fc
demonstr
highest
affin
induc
highest
titer
neutral
antibodi
immun
mice
rabbit
anoth
rbd
fragment
formul
aluminum
hydroxid
alum
investig
rhesu
macaqu
model
anim
immun
higher
dose
vaccin
rrbd
admix
mg
alum
adjuv
show
less
sever
pneumonia
decreas
viral
load
upon
challeng
merscov
compar
lower
dose
group
recent
though
group
korea
observ
high
mutat
rate
isol
merscov
sever
patient
seen
mutat
rbd
protein
display
reduc
bind
affin
host
cell
receptor
make
viru
less
virul
wildtyp
possibl
also
contribut
viru
evad
host
immun
system
therefor
shi
et
al
suggest
epitopebas
vaccin
design
identifi
highli
conserv
region
produc
neutral
antibodi
cellular
immun
merscov
base
silico
protein
antigen
predict
structur
analysi
nucleocapsid
n
protein
merscov
probabl
antigen
protein
number
put
lymphocyt
epitop
peptid
identifi
n
protein
nevertheless
suggest
epitop
undergo
comprehens
vitro
vivo
studi
effici
use
vaccin
merscov
use
dna
vaccin
base
transfect
plasmid
dna
encod
antigen
protein
host
cell
subsequ
express
foreign
gene
order
induc
potent
immun
respons
diseas
interest
undoubtedli
first
glanc
nucleic
acid
immun
appear
attract
vaccin
platform
fast
vaccin
develop
clean
safeti
profil
low
product
cost
howev
spite
promis
data
preclin
anim
studi
dna
vaccin
yet
fulli
success
human
exampl
dengu
dna
vaccin
combin
dna
protein
vaccin
vaccin
research
center
niaid
dna
protein
boost
boost
mous
nhp
receptorbind
domain
new
york
blood
center
utmb
bcm
rbd
fragment
mous
transgen
mous
rabbit
show
excel
antidengu
cellular
humor
immun
respons
nonhuman
primat
howev
fail
produc
neutral
antibodi
human
subject
research
develop
merscov
dna
vaccin
focus
protein
engin
plasmid
dna
encod
fulllength
protein
sequenc
synthet
dna
vaccin
merscov
studi
mice
larg
anim
model
nonhuman
primatesnhp
camel
result
show
vaccin
capabl
induc
proteinspecif
neutral
antibodi
anim
intriguingli
studi
reveal
vaccin
nhp
protect
fail
demonstr
clinic
radiograph
sign
pneumonia
post
mer
viral
challeng
earli
firstinhuman
trial
mer
vaccin
begun
particip
receiv
mer
dna
vaccin
codevelop
inovio
pharmaceut
geneon
life
scienc
inc
altern
approach
graham
cowork
propos
combin
dna
vaccin
subunit
protein
primeboost
scheme
rhesu
macaqu
immun
spike
dna
vaccin
follow
protein
adjuv
aluminum
phosphat
yield
neutral
antibodi
show
fewer
sign
pulmonari
diseas
anim
vaccin
protein
merscov
vaccin
target
camel
develop
use
viral
vector
vaccin
technolog
adenovir
vector
encod
fulllength
merscov
protein
extracellular
domain
protein
preclin
studi
show
vaccin
dromedari
camel
mount
neutral
antibodi
respons
merscov
vitro
guo
et
al
highlight
intramuscular
rout
administ
adenovirusbas
vaccin
merscov
protein
could
affect
antigenspecif
cell
respons
immun
mice
late
viral
vector
vaccin
merscov
construct
use
modifi
vaccinia
viru
ankara
mva
mvamerss
recombin
viru
genet
stabl
primari
chicken
embryo
fibroblast
cef
without
need
addit
animalderiv
compon
abl
protect
human
mice
merscov
challeng
phase
clinic
trial
human
vaccin
announc
support
german
center
infect
research
difz
novavax
collabor
team
univers
maryland
produc
merscov
fulllength
nanos
amphiphil
spike
protein
aggreg
use
recombin
baculoviru
construct
cell
formul
alum
even
greater
extent
novavax
saponinbas
adjuv
high
titer
neutral
antibodi
merscov
relat
sarscov
observ
howev
plan
clinic
trial
made
public
yet
anoth
approach
toward
mer
vaccin
target
camel
one
reservoir
viru
accord
crosssect
serolog
survey
provinc
saudi
arabia
individu
seropreval
merscov
antibodi
significantli
higher
camelexpos
individu
gener
popul
scientist
netherland
germani
spain
shown
modifi
vaccinia
viru
ankara
vaccin
express
merscov
spike
protein
mva
confer
mucos
immun
dromedari
camel
use
primeboost
approach
dromedari
camel
immun
intranas
well
intramuscularli
week
challeng
intranas
merscov
viru
anim
show
typic
mild
clinic
symptom
mer
infect
speci
signific
reduct
excret
infecti
viru
particl
well
reduct
viral
rna
immun
camel
observ
howev
concern
reduct
might
suffici
disrupt
spread
viru
vaccin
might
provid
longlast
immun
addit
sinc
diseas
caus
signific
morbid
camel
perceiv
reluct
among
camel
owner
anim
vaccin
first
place
ad
benefit
mva
vaccin
though
observ
vaccin
provid
crossprotect
camelpox
viru
might
treatment
attract
anim
owner
order
character
viral
pathogenesi
evalu
therapeut
option
merscov
research
reli
anim
model
mimick
clinic
cours
patholog
observ
human
contrast
sar
anim
model
age
mice
display
patholog
chang
postinfect
mice
infect
merscov
show
clinic
sign
infect
weight
loss
addit
syrian
hamster
ferret
known
suscept
sarscov
fail
infect
merscov
nonhuman
primat
nhp
common
marmoset
model
test
suitabl
merscov
model
upon
combin
variou
inocul
rout
intratrach
ocular
oral
intranas
use
infecti
dose
merscov
rhesu
macaqu
develop
transient
lower
respiratori
tract
infect
mild
clinic
diseas
without
mortal
hand
merscov
infect
common
marmoset
develop
progress
sever
pneumonia
although
nhp
suffici
good
model
studi
mer
differ
sever
work
nhp
costli
henc
establish
transgen
rodent
anim
model
crucial
move
forward
develop
vaccin
therapeut
method
merscov
compar
small
anim
cell
line
transfect
human
hamster
gene
observ
human
cell
line
enabl
merscov
replic
fulli
permiss
merscov
infect
result
weight
loss
acut
inflammatori
respons
within
lung
brain
anim
transgen
mice
immun
rbd
fragment
fuse
fc
fragment
protect
challeng
high
dose
ld
viru
anoth
transgen
mous
recent
creat
use
express
vector
either
cytokeratin
surfact
protein
c
spc
promot
transgen
mice
exhibit
milder
diseas
phenotyp
emerg
reemerg
diseas
pandem
potenti
major
drive
forc
vaccin
develop
human
coronavirus
pandem
outbreak
sarscov
necessit
develop
blueprint
global
respons
type
threat
merscov
reach
fourth
year
emerg
initi
technolog
advanc
enabl
one
dnabas
vaccin
quickli
enter
phase
human
trial
process
arguabl
acceler
key
inform
strateg
vaccin
develop
obtain
prior
sarscov
outbreak
nevertheless
process
bring
vaccin
clinic
remain
lengthi
cumbersom
new
infecti
diseas
shift
focu
away
mer
risk
vaccin
develop
process
remain
unfinish
pick
next
coronaviru
emerg
conflict
interest
author
declar
conflict
interest
human
anim
right
inform
consent
articl
contain
studi
human
anim
subject
perform
author
